View Alert


Originator: CMO Messaging

From: CMO Messaging

Issue date: 28-Nov-2021 19:07:59

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Social Care Providers (registered with CAS)
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Out of hours contacts
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Important information for immediate action

Title: Update on COVID-19 Variant B.1.1.529

Broadcast content: Data is still emerging on Variant B.1.1.529 but it is currently a significant concern. It is now designated as a Variant of Concern by the World Health Organisation and the UK. The New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) met on 26/11/2021, this alert provides a summary of what the group discussed alongside the latest advice for the public and healthcare workers.

We also attach a note on Omicron enhanced surveillance for testing laboratories, for your information.


Additional information: NHS England and NHS Improvement Regional Offices: please cascade to community pharmacy, dental and optometry contractors.

Alert reference: CEM/CMO/2021/019

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency